WindMIL Therapeutics Leadership

Specialties: Clinical Trial Design, Immune Monitoring, Scientific Consulting, Immunotherapies, Immunovaccines, T cell activation, Multiple Myeloma

Don Hayden is a Senior Advisor to Prospect Venture Partners. Mr. Hayden brings to Prospect the experiences and perspective resulting from a highly-successful 25 year career with Bristol-Myers Squibb Company as well as the insights gained from key roles at a number of smaller, more entrepreneurial pharmaceutical and biotech companies over the past 5 years. At Bristol-Myers Squibb, Mr. Hayden served as President of Global Pharmaceuticals; Executive Vice President and President, Americas, overseeing two major pharmaceutical units and two healthcare businesses; Executive Vice President of the Health Care Group; President of Oncology and Immunology; and Senior Vice President for Worldwide Franchise Management and Business Development. Since leaving Bristol-Myers Squibb in early 2006, Mr. Hayden has served as Chairman of Gloucester Pharmaceuticals, Vitae Pharmaceuticals, Insmed, and Azelon Pharmaceuticals, as Lead Director of Amicus Therapeutics, and as a Director of Otsuka Pharmaceuticals and Nora Therapeutics. Mr. Hayden received his undergraduate degree from Harvard University and has an M.B.A. from Indiana University.

Monil Shah is a Chief Development Officer at WindMIL Therapeutics Inc. He has experience at Amgen; PARATEK PHARMACEUTICALS, INC.; and FIBROGEN INC and has worked as Chief Operating Officer at IRX Therapeutics, Head:Medical Affairs at Bristol Myers Squibb, and VP:Clinical Operations & Dev at ASSEMBLY BIOSCIENCES INC. Monil studied at Florida Institute of Technology Aviation and Rutgers University.

Patrick 'Pat' Fabbio is a Board Member at BEYONDSPRING INC., Chief Financial Officer at Intranasal Therapeutics, and Chief Financial Officer at WindMIL Therapeutics Inc and is based in New York City, New York. He has experience at Sanofi-Aventis SA and Pricewaterhouse Coopers (PwC) and has worked as VP:Commercial Ops at Unipath Diagnostics Co., Senior VP/CFO at PROGENICS PHARMACEUTICALS, and Corporate Controller at Biomatrix Inc. Patrick works or has worked as MEMBER at US Life Cycle Mgmt & Base Business.. He attended Pace University and New York University.

Specialties: Clinical Trial Design, Immune Monitoring, Scientific Consulting, Immunotherapies, Immunovaccines, T cell activation, Multiple Myeloma

Don Hayden is a Senior Advisor to Prospect Venture Partners. Mr. Hayden brings to Prospect the experiences and perspective resulting from a highly-successful 25 year career with Bristol-Myers Squibb Company as well as the insights gained from key roles at a number of smaller, more entrepreneurial pharmaceutical and biotech companies over the past 5 years. At Bristol-Myers Squibb, Mr. Hayden served as President of Global Pharmaceuticals; Executive Vice President and President, Americas, overseeing two major pharmaceutical units and two healthcare businesses; Executive Vice President of the Health Care Group; President of Oncology and Immunology; and Senior Vice President for Worldwide Franchise Management and Business Development. Since leaving Bristol-Myers Squibb in early 2006, Mr. Hayden has served as Chairman of Gloucester Pharmaceuticals, Vitae Pharmaceuticals, Insmed, and Azelon Pharmaceuticals, as Lead Director of Amicus Therapeutics, and as a Director of Otsuka Pharmaceuticals and Nora Therapeutics. Mr. Hayden received his undergraduate degree from Harvard University and has an M.B.A. from Indiana University.